CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice

Journal of Lipid Research

Volumn 54, Issue 11, 2013, Pages 2988-2997

  Nassir, Fatiha ^a   Adewole, Okunade L ^a   Brunt, Elizabeth M ^a   Abumrad, Nada A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenase; Kupffer cells; Triglyceride

Indexed keywords

APOLIPOPROTEIN B; CD36 ANTIGEN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY LIVER; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; LIPOGENESIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CYCLOOXYGENASE; KUPFFER CELLS; TRIGLYCERIDE;

ANIMALS; ANTIGENS, CD36; FATTY LIVER; GENE KNOCKOUT TECHNIQUES; HUMANS; LIPOPROTEINS, VLDL; LIVER; MICE; PROSTAGLANDINS;

EID: 84885993664     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M037812     Document Type: Article

References (59)

1. Anstee, Q. M., and R. D. Goldin. 2006. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87: 1-16.
2. Cohen, J. C., J. D. Horton, and H. H. Hobbs. 2011. Human fatty liver disease: old questions and new insights. Science. 332: 1519-1523.
3. Degrace-Passilly, P., and P. Besnard. 2012. CD36 and taste of fat. Curr. Opin. Clin. Nutr. Metab. Care. 15: 107-111.
4. Pepino, M. Y., L. Love-Gregory, S. Klein, and N. A. Abumrad. 2012. The fatty acid translocase gene CD36 and lingual lipase influence oral sensitivity to fat in obese subjects. J. Lipid Res. 53: 561-566.
5. Su, X., and N. A. Abumrad. 2009. Cellular fatty acid uptake: a pathway under construction. Trends Endocrinol. Metab. 20: 72-77.
6. Glatz, J. F., J. J. Luiken, and A. Bonen. 2010. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol. Rev. 90: 367-417.
7. Abumrad, N. A., and N. O. Davidson. 2012. Role of the gut in lipid homeostasis. Physiol. Rev. 92: 1061-1085.
8. Sundaresan, S., R. Shahid, T. E. Riehl, R. Chandra, F. Nassir, W. F. Stenson, R. A. Liddle, and N. A. Abumrad. 2013. CD36-dependent signaling mediates fatty acid-induced gut release of secretin and cholecystokinin. FASEB J. 27: 1191-1202.
9. Malerod, L., K. Juvet, T. Gjoen, and T. Berg. 2002. The expression of scavenger receptor class B, type I (SR-BI) and caveolin-1 in parenchymal and nonparenchymal liver cells. Cell Tissue Res. 307: 173-180. (Pubitemid 34158529)
10. Memon, R. A., J. Fuller, A. H. Moser, P. J. Smith, C. Grunfeld, and K. R. Feingold. 1999. Regulation of putative fatty acid transporters and Acyl-CoA synthetase in liver and adipose tissue in ob/ob mice. Diabetes. 48: 121-127. (Pubitemid 29019362)
11. Koonen, D. P., R. L. Jacobs, M. Febbraio, M. E. Young, C. L. Soltys, H. Ong, D. E. Vance, and J. R. Dyck. 2007. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 56: 2863-2871. (Pubitemid 350223619)
12. He, J., J. H. Lee, M. Febbraio, and W. Xie. 2011. The emerging roles of fatty acid translocase/CD36 and the aryl hydrocarbon receptor in fatty liver disease. Exp. Biol. Med. 236: 1116-1121.
13. Tappy, L., and K-A. Lê. 2010. Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 90: 23-46.
14. Hajri, T., X. X. Han, A. Bonen, and N. A. Abumrad. 2002. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. J. Clin. Invest. 109: 1381-1389. (Pubitemid 34546903)
15. Miquilena-Colina, M. E., E. Lima-Cabello, S. Sanchez-Campos, M. V. Garcia-Mediavilla, M. Fernandez-Bermejo, T. Lozano-Rodriguez, J. Vargas-Castrillon, X. Buque, B. Ochoa, P. Aspichueta, et al. 2011. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut. 60: 1394-1402.
16. Fabbrini, E., B. S. Mohammed, F. Magkos, K. M. Korenblat, B. W. Patterson, and S. Klein. 2008. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 134: 424-431. (Pubitemid 351173050)
17. Love-Gregory, L., R. Sherva, T. Schappe, J. S. Qi, J. McCrea, S. Klein, M. A. Connelly, and N. A. Abumrad. 2011. Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile. Hum. Mol. Genet. 20: 193-201.
18. El-Yassimi, A., A. Hichami, P. Besnard, and N. A. Khan. 2008. Linoleic acid induces calcium signaling, Src kinase phosphorylation, and neurotransmitter release in mouse CD36-positive gustatory cells. J. Biol. Chem. 283: 12949-12959.
19. Pietka, T. A., M. S. Sulkin, O. Kuda, W. Wang, D. Zhou, K. A. Yamada, K. Yang, X. Su, R. W. Gross, J. M. Nerbonne, et al. 2012. CD36 protein influences myocardial Ca2+ homeostasis and phospholipid metabolism: conduction anomalies in CD36-deficient mice during fasting. J. Biol. Chem. 287: 38901-38912.
20. Kuda, O., C. M. Jenkins, J. R. Skinner, S. H. Moon, X. Su, R. W. Gross, and N. A. Abumrad. 2011. CD36 protein is involved in storeoperated calcium flux, phospholipase A2 activation, and production of prostaglandin E2. J. Biol. Chem. 286: 17785-17795.
21. Tran, T. T. T., H. Poirier, L. Clément, F. Nassir, M. M. A. L. Pelsers, V. Petit, P. Degrace, M-C. Monnot, J. F. C. Glatz, N. A. Abumrad, et al. 2011. Luminal lipid regulates CD36 levels and downstream signaling to stimulate chylomicron synthesis. J. Biol. Chem. 286: 25201-25210.
22. Björnsson, O. G., J. D. Sparks, C. E. Sparks, and G. F. Gibbons. 1992. Prostaglandins suppress VLDL secretion in primary rat hepatocyte cultures: relationships to hepatic calcium metabolism. J. Lipid Res. 33: 1017-1027.
23. Pérez, S., P. Aspichueta, B. Ochoa, and Y. Chico. 2006. The 2-series prostaglandins suppress VLDL secretion in an inflammatory condition-dependent manner in primary rat hepatocytes. Biochim. Biophys. Acta. 176: 160-171.
24. Noushmehr, H., E. D'Amico, L. Farilla, H. Hui, K. A. Wawrowsky, W. Mlynarski, A. Doria, N. A. Abumrad, and R. Perfetti. 2005. Fatty acid translocase (FAT/CD36) Is localized on insulin-containing granules in human pancreatic β-cells and mediates fatty acid effects on insulin secretion. Diabetes. 54: 472-481.
25. Takahashi, Y., Y. Soejima, and T. Fukusato. 2012. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 18: 2300-2308.
26. Perfield 2nd, J. W., L. C. Ortinau, R. T. Pickering, M. L. Ruebel, G. M. Meers, and R. S. Rector. 2013. Altered hepatic lipid metabolism contributes to nonalcoholic fatty liver disease in leptin-deficient Ob/Ob mice. J. Obes. 2013: 296537.
27. Moon, Y. A., G. Liang, X. Xie, M. Frank-Kamenetsky, K. Fitzgerald, V. Koteliansky, M. S. Brown, J. L. Goldstein, and J. D. Horton. 2012. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 15: 240-246.
28. Li, X., F. Catalina, S. M. Grundy, and S. Patel. 1996. Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. J. Lipid Res. 37: 210-220.
29. Pan, X., Y. Zhang, L. Wang, and M. M. Hussain. 2010. Diurnal regulation of MTP and plasma triglyceride by CLOCK is mediated by SHP. Cell Metab. 12: 174-186.
30. Drover, V. A., M. Ajmal, F. Nassir, N. O. Davidson, A. M. Nauli, D. Sahoo, P. Tso, and N. A. Abumrad. 2005. CD36 deficiency impairs intestinal lipid secretion and clearance of chylomicrons from the blood. J. Clin. Invest. 115: 1290-1297. (Pubitemid 40629048)
31. Nauli, A. M., F. Nassir, S. Zheng, Q. Yang, C. M. Lo, S. B. Vonlehmden, D. Lee, R. J. Jandacek, N. A. Abumrad, and P. Tso. 2006. CD36 is important for chylomicron formation and secretion and may mediate cholesterol uptake in the proximal intestine. Gastroenterology. 131: 1197-1207.
32. Sundaram, M., and Z. Yao. 2010. Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion. Nutr. Metab. (Lond.). 7: 35.
33. Kuiper, J., F. J. Zijlstra, J. A. Kamps, and T. J. Van Berkel. 1989. Cellular communication inside the liver. Binding, conversion and metabolic effect of prostaglandin D2 on parenchymal liver cells. Biochem. J. 262: 195-201. (Pubitemid 19220949)
34. Diraison, F., P. Moulin, and M. Beylot. 2003. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterifi ed fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 29: 478-485. (Pubitemid 37474259)
35. Ge, F., S. Zhou, C. Hu, H. Lobdell, and P. D. Berk. 2010. Insulinand leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice. Am. J. Physiol. Gastrointest. Liver Physiol. 299: G855-G866.
36. Digel, M., R. Ehehalt, and J. Fullekrug. 2010. Lipid droplets lighting up: insights from live microscopy. FEBS Lett. 584: 2168-2175.
37. Wolins, N. E., D. L. Brasaemle, and P. E. Bickel. 2006. A proposed model of fat packaging by exchangeable lipid droplet proteins. FEBS Lett. 580: 5484-5491. (Pubitemid 44465908)
38. Memon, R. A., C. Grunfeld, A. H. Moser, and K. R. Feingold. 1994. Fatty acid synthesis in obese insulin resistant diabetic mice. Horm. Metab. Res. 26: 85-87. (Pubitemid 24089215)
39. Wang, Y., D. Botolin, J. Xu, B. Christian, E. Mitchell, B. Jayaprakasam, M. G. Nair, J. M. Peters, J. V. Busik, L. K. Olson, et al. 2006. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J. Lipid Res. 47: 2028-2041. (Pubitemid 44401991)
40. Enomoto, N., K. Ikejima, S. Yamashina, A. Enomoto, T. Nishiura, T. Nishimura, D. A. Brenner, P. Schemmer, B. U. Bradford, C. A. Rivera, et al. 2000. Kupffer cell-derived prostaglandin E2 is involved in alcohol-induced fat accumulation in rat liver. Am. J. Physiol. Gastrointest. Liver Physiol. 279: G100-G106. (Pubitemid 30612687)
41. Cho, H. J., H. C. Kang, S. A. Choi, Y. C. Ju, H. S. Lee, and H. J. Park. 2005. The possible role of Ca2+ on the activation of microsomal triglyceride transfer protein in rat hepatocytes. Biol. Pharm. Bull. 28: 1418-1423.
42. Higashi, Y., H. Itabe, H. Fukase, M. Mori, Y. Fujimoto, and T. Takano. 2003. Transmembrane lipid transfer is crucial for providing neutral lipids during very low density lipoprotein assembly in endoplasmic reticulum. J. Biol. Chem. 278: 21450-21458. (Pubitemid 36792541)
43. Burke, J. E., and E. A. Dennis. 2009. Phospholipase A2 structure/function, mechanism, and signaling. J. Lipid Res. 50 (Suppl): S237-S242.
44. Dennis, E. A., J. Cao, Y. H. Hsu, V. Magrioti, and G. Kokotos. 2011. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem. Rev. 111: 6130-6185.
45. Nishimaki-Mogami, T., Z. Yao, and K. Fujimori. 2002. Inhibition of phosphatidylcholine synthesis via the phosphatidylethanolamine methylation pathway impairs incorporation of bulk lipids into VLDL in cultured rat hepatocytes. J. Lipid Res. 43: 1035-1045. (Pubitemid 34760874)
46. Shelness, G. S., and J. A. Sellers. 2001. Very-low-density lipoprotein assembly and secretion. Curr. Opin. Lipidol. 12: 151-157. (Pubitemid 32242922)
47. Tran, K., Y. Wang, C. J. DeLong, Z. Cui, and Z. Yao. 2000. The assembly of very low density lipoproteins in rat hepatoma McARH7777 cells is inhibited by phospholipase A2 antagonists. J. Biol. Chem. 275: 25023-25030. (Pubitemid 30626612)
48. Dramane, G., S. Abdoul-Azize, A. Hichami, T. Vogtle, S. Akpona, C. Chouabe, H. Sadou, B. Nieswandt, P. Besnard, and N. A. Khan. 2012. STIM1 regulates calcium signaling in taste bud cells and preference for fat in mice. J. Clin. Invest. 122: 2267-2282.
49. Itagaki, K., B. E. Barton, T. F. Murphy, S. Taheri, P. Shu, H. Huang, and M. L. Jordan. 2011. Eicosanoid-induced store-operated calcium entry in dendritic cells. J. Surg. Res. 169: 301-310.
50. Meves, H. 2008. Arachidonic acid and ion channels: an update. Br. J. Pharmacol. 155: 4-16.
51. Siddiqi, S., U. Saleem, N. A. Abumrad, N. O. Davidson, J. Storch, S. A. Siddiqi, and C. M. Mansbach 2nd. 2010. A novel multiprotein complex is required to generate the prechylomicron transport vesicle from intestinal ER. J. Lipid Res. 51: 1918-1928.
52. Bodmer, M., M. Sulz, S. Stadlmann, A. Droll, L. Terracciano, and S. Krahenbuhl. 2006. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion. 74: 28-32. (Pubitemid 44835688)
53. Godbole, V. Y., M. L. Grundleger, and S. W. Thenen. 1980. Early development of lipogenesis in genetically obese (ob/ob) mice. Am. J. Physiol. 239: E265-E268. (Pubitemid 10008816)
54. Goldberg, I. J., and H. N. Ginsberg. 2006. Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology. 130: 1343-1346.
55. Kawano, Y., and D. E. Cohen. 2013. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J. Gastroenterol. 48: 434-441.
56. Tanaka, T., T. Nakata, T. Oka, T. Ogawa, F. Okamoto, Y. Kusaka, K. Sohmiya, K. Shimamoto, and K. Itakura. 2001. Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations. J. Lipid Res. 42: 751-759. (Pubitemid 32507174)
57. Greco, D., A. Kotronen, J. Westerbacka, O. Puig, P. Arkkila, T. Kiviluoto, S. Laitinen, M. Kolak, R. M. Fisher, A. Hamsten, et al. 2008. Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G1281-G1287.
58. Zhu, L., S. S. Baker, W. Liu, M. H. Tao, R. Patel, N. J. Nowak, and R. D. Baker. 2011. Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism. 60: 1001-1011.
59. Donnelly, K. L., C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115: 1343-1351. (Pubitemid 40629054)